Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the potential impact of the Soft Drinks Industry Levy on the level of sugar intake by children.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Soft Drinks Industry Levy (SDIL) came into law on 5 April 2018, having been announced in 2016. Between 2015 and 2024 sugar levels in drinks in scope of the levy reduced by 47%, and while no formal assessment of the impact on children has been undertaken, the scale of reduction will have an impact on the sugar intake of children.
Data from the National Diet and Nutrition Survey (NDNS), an ongoing Government survey of food consumption, nutrient intake, and nutrient status in the United Kingdom, showed a fall in sugar intakes between 2014 to 2019, in older children and adolescents. This appears to be partly driven by soft drinks contributing less to sugar intakes, likely as a result of the changes made to drinks in scope of the SDIL.
The latest results for 2019 to 2023 show that sugar intakes in children remain approximately double the maximum recommendation and children aged 11 to 18 years old are the highest consumers of sugar sweetened soft drinks. Diets high in sugar increase the risk of dental caries as well as weight gain, which can ultimately result in living with overweight and obesity and related adverse health outcomes. The NDNS will continue to monitor sugar intakes following reformulation of drinks in scope of the SDIL.
Academic modelling indicates that reductions in sugar from drinks subject to the SDIL may have prevented 5,000 cases of obesity in girls aged ten to 11 years old, with greater impact on those attending schools in the most deprived areas. Modelling data also suggests that the changes resulting from the SDIL may have reduced hospital admissions for dental caries related tooth extractions in those aged zero to nine years old and for asthma related issues in those aged five to 18 years old.
Following formal consultation, two changes to the SDIL were announced in the 2025 Autumn Budget which will apply from 1 January 2028:
The Department carried out a health benefits assessment to estimate the sugar and calorie reduction from these changes through product reformulation and consumer substitution to alternative drinks.
This analysis estimates a sugar reduction equivalent to per person per day calorie reductions of 0.3 kcal in five- to ten-year-olds, 0.4 kcal in 11- to 18-year-olds, 0.3 kcal in 19- to 64-year-olds, and 0.2 kcal in those aged 65 years old and over. This is equivalent to approximately four million kcal per day in children and 13 million kcal per day in adults.
Asked by: Sarah Dyke (Liberal Democrat - Glastonbury and Somerton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential impact of school milk consumption on children’s oral health, including rates of dental decay.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Water and milk are the only recommended drinks to give children regarding their oral health. Milk and dairy foods, or dairy alternatives, are an important part of a healthy balanced diet, as depicted by the United Kingdom’s national food model, the Eatwell Guide. The School Food Standards state that lower fat milk and lactose-reduced milk must be available every school day, during school hours. Whole milk may be provided for pupils up to the end of the school year in which they turn five years old. Sugars naturally present in unsweetened milk and milk products are not classed as ‘free sugars’, which should be limited to reduce the risk of tooth decay. Further information is available at the following link:
https://www.nhs.uk/live-well/eat-well/food-types/how-does-sugar-in-our-diet-affect-our-health/
We have invested £11 million in 147 local authorities in 2025/26, alongside a five-year partnership with Colgate-Palmolive, to rollout a national supervised toothbrushing programme for up to 600,000 three- to five-year-olds in the 20% most deprived areas of England. The programme will tackle poor oral health by ensuring children learn positive habits and prevention of tooth decay.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to provide emergency day-to-day funding to hospices; and whether he will commit to releasing (a) £100 million in emergency funding now and (b) a further £100 million in April 2026 to stabilise hospice services and protect patient care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Children and young people’s hospices have received £26 million of revenue funding for 2025/26 and we are also providing approximately £80 million of revenue funding for children and young people’s hospices over the next three financial years, 2026/27 to 2028/29, giving them stability to plan ahead and focus on what matters most, caring for their patients.
In December 2024, we announced that we were providing £100 million of capital funding for eligible adult and children’s hospices in England. This was split across two financial years, with hospices receiving £25 million to spend in 2024/25 and £75 million to spend in 2025/26.
We are pleased to say that we can now confirm we are providing a further £25 million in capital funding for hospices to spend in 2025/26.
We are in a challenging fiscal position across the board. At this time, we are not in a position to offer any additional funding beyond that outlined above. However, we are supporting the hospice sector in other ways.
The Government is developing a Palliative Care and End of Life Care Modern Service Framework (MSF) for England. As part of the MSF, we will consider contracting and commissioning arrangements. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.
Asked by: David Chadwick (Liberal Democrat - Brecon, Radnor and Cwm Tawe)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what assessment his Department has made of the adequacy of the Child Maintenance Service policy in establishing the Paying Parent, in the context of changes in societal norms and the increase in co-parenting and shared parenting arrangements.
Answered by Andrew Western - Parliamentary Under-Secretary (Department for Work and Pensions)
The person providing primary care of the child and with whom the child lives is entitled to make an application for child maintenance. This is known as the receiving parent. The receiving parent is determined by which parent looks after the child most of the time. For example, with whom the child has their home and who usually provides day to day care for the child.
The Child Maintenance Calculation can be amended to reflect co-parenting and shared parenting arrangements. A paying parent’s maintenance liability can be reduced where they have overnight care of a child for whom they pay maintenance. This reduction is intended to broadly reflect the cost associated with any overnight care given. The paying parent must have overnight care of any qualifying children for at least 52 nights a year, equivalent to 1 night per week. The amount payable is reduced to a maximum of 50 per cent within bands based on the number of days overnight care is provided over a 12-month period.
The CMS uses bands based on the number of days overnight care is provided, to ensure a fair, consistent, and administratively efficient method of accounting for the costs borne by each parent.
If the CMS is satisfied that both parents have equal day-to-day care for the child, in addition to sharing overnight care, there is no requirement for either parent to pay child maintenance.
There is no statutory definition of day-to-day care, our definition is broadly aligned with that of Child Benefit, where an ‘overall care test’ is used. This provides consistency across government and receipt of Child Benefit is regarded as a good indicator of who is entitled to child maintenance payments.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to increase public awareness of the Medicines and Healthcare products Regulatory Agency Yellow Card scheme for reporting medicine side effects and product issues.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to improving patient safety and strategically runs regular public health campaigns to raise awareness of patient safety in healthcare products and the importance of reporting to the Yellow Card scheme, which relies on voluntary reporting by healthcare professionals and the public, including patients, parents, and care givers. Further information on the MHRA is available at the following link:
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
A primary platform for education and awareness is the MHRA’s dedicated Yellow Card scheme website, which is regularly updated with educational resources, including Continuing Professional Development accredited e-learning modules, waiting-room videos, posters, and real-world case studies to support understanding of how and what to report as well as the importance of reporting. In 2025, the MHRA launched a new Yellow Card Partner Toolkit containing a package of materials specifically designed to support other organisations and networks in encouraging patient reporting.
To strengthen local engagement with the public, the MHRA commissions six Yellow Card Centres across the United Kingdom, covering the North and Yorkshire, the North West, the West Midlands, Scotland, Wales, and Northern Ireland, and which focus on education and the promotion of reporting with the public and healthcare professionals, as well as their representative organisations within their regions.
Additionally, all MHRA safety alerts and guidance signpost users to the Yellow Card scheme, and by law, every patient information leaflet that comes with a medicine includes information signposting patients to report suspected side effects via the Yellow Card scheme. There is also information on the importance of reporting to the Yellow Card scheme on all repeat paper prescriptions given to patients.
On World Patient Safety Day, most recently 17 September 2025, the MHRA announced that statutory relationships, sex, and health education guidance for schools in England would, for the first time, include information on recognising side effects and reporting them via the Yellow Card scheme. This initiative introduces children and young people to patient safety early, empowering them to speak up and contribute to safer healthcare.
The MHRA also proactively promotes awareness through presence at conferences such as the annual Health and Safety Journal Patient Safety Congress. In addition, the MHRA also supports a number of campaigns including MedSafetyWeek, which is now an annual international social media campaign which includes 117 countries that the MHRA initiated 10 years ago, to raise awareness of medicines safety and adverse incident reporting.
The MHRA has worked with the National Health Service to ensure that there are links to Yellow Card across every single NHS page relating to a medicine or vaccine, and the MHRA is also building upon this by working with NHS colleagues to support better links between the NHS app and Yellow Card, aiming for increased visibility of the Yellow Card scheme and improved reporting of suspected reactions by the public.
Together, these measures increase public awareness of the Yellow Card scheme, helping protect patient safety and strengthen monitoring of medicines and medical devices.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his Department’s policy to introduce mandatory NHS testing for paediatric type 1 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.
NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.
NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.
Asked by: Andrew Rosindell (Reform UK - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the diagnosis of type 1 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.
NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.
NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.
Asked by: Liz Jarvis (Liberal Democrat - Eastleigh)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps she is taking to help ensure continuity of (a) assessments and (b) support across local authorities for children of service personnel with special educational needs and disabilities when families relocate.
Answered by Georgia Gould - Minister of State (Education)
All those with statutory responsibilities towards children of service personnel with special education needs and disability (SEND), should ensure that the impact of their policies, administrative processes and patterns of provision do not disadvantage such children when families relocate.
Statutory guidance is clear that when a child moves home across local authority boundaries, the education, health and care plan must be transferred from the ‘old’ local authority to the ‘new’ local authority on the day of the move or within 15 working days from when the old local authority first becomes aware of the move. Upon receiving the plan, the new local authority must arrange the special educational provision set out in it, although a child may have to be placed in a school other than the one named on the plan if the distance of the move makes it impractical to send the child to the named school.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to encourage collaboration between NHS Trusts and pharmaceutical companies to enhance cancer clinical trials.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
We are incentivising clinical trials and strengthening collaboration between pharmaceutical companies and National Health Service trusts by streamlining processes and cutting set‑up times to 150 days by March 2026, ensuring the United Kingdom offers a faster, more competitive environment for delivering high‑quality research.
The Department funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. This includes Experimental Cancer Medicine Centres, co-funded by NIHR, Cancer Research UK, and the Little Princess Trust, which form a UK-wide network that brings together world leading laboratory and clinical researchers to deliver pioneering early phase cancer trials for adults and children. Additionally, the Medicines and Healthcare products Regulatory Agency will introduce a 14-day assessment route for phase 1 trials, adopting an innovative stepwise approach, restoring a rapid pathway for the earliest testing of new medicines in people, a key draw for global pharmaceutical companies deciding where to base their research.
NHS England is delivering specific collaborative initiatives with industry such as the Cancer Vaccine Launch Pad (CVLP). The NHS CVLP is a platform that is speeding up access to clinical trials for cancer vaccines and immunotherapies for patients who have been diagnosed with cancer. The CVLP platform is designed to be company and clinical trial agnostic. Different companies have been involved in the CVLP and trials in the CVLP portfolio have included cancers such as head and neck cancer melanoma and colorectal cancer.
35 Commercial Research Delivery Centres (CRDCs), including primary care been established largely within NHS trusts. CRDCs will expand capacity, streamline set-up, and give patients faster access to innovative treatments and clinical trials, including those concerning cancer.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of extending free milk eligibility to the end of the academic year in which a child turns five.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Nursery Milk Scheme is a statutory scheme which allows early years childcare settings to reclaim the cost of providing one-third of a pint of milk per day to children under the age of five years old who attend a setting for two or more hours per day. Schools can claim reimbursement from the scheme in respect of their pupils aged under five years old.
There are no plans to extend eligibility for the Nursery Milk Scheme to cover children until the end of the academic year, during which they reach their fifth birthday. Separate legislation allows pupils from lower-income families, and who are eligible for free school meals, to continue to receive free milk at school after the age of five years old.